In the age of precision medicine, genetic analyses are playing an increasingly key role in the preventive diagnosis and treatment of skin cancers. The skin, being the largest organ in the human body, incorporates the damage caused by genetic mutations normally detectable in diseases mainly involving the skin (i.e. CKN2A mutation) as well as other mutations (i.e. MSH2 in Lynch syndrome), which usually affect other organs but can cause a greater predisposition to tumors also in the skin. For this reason, knowing the clinical-pathological and genetic aspects of patients affected by these mutations allows for the prevention of skin cancer onset. Further, it also allows for improved prognosis and therapeutic setting, possibly addressing these patients in scheduled follow-ups.
The goal of this Research Topic is to summarize the main genetic mutations in melanocytic and non-melanocytic tumor. Knowledge of the main genetic mutations in cutaneous malignancies allows an increasingly targeted therapy for this class of patients and more efficient follow-ups. Furthermore, the knowledge of genetic mutations in cutaneous tumors and the relative clinic-pathological features, will allow to increase and broaden the therapeutic perspectives, reducing morbidity and mortality, providing important information about the health of the person tested in the absence of definitive treatment, or assisting therapeutic decision-making.
Here, authors are welcomed address the following themes:
•Reviews, original articles and case reports that focus on the main genetic mutations in melanocytic and non-melanocytic tumors are welcome.
•Reviews, original articles and case reports that focus on cutaneous and non-cutaneous genetic mutations that may induce the onset of skin tumors are welcome
•Reviews, original articles and case reports that focus on therapeutic response to topical and systemic treatments of cutaneous tumors which show specific genetic mutations are welcome
• Reviews and original articles that focus on cutaneous diagnostic and baseline clinic-pathologic features in general mutated patients are welcome.
In the age of precision medicine, genetic analyses are playing an increasingly key role in the preventive diagnosis and treatment of skin cancers. The skin, being the largest organ in the human body, incorporates the damage caused by genetic mutations normally detectable in diseases mainly involving the skin (i.e. CKN2A mutation) as well as other mutations (i.e. MSH2 in Lynch syndrome), which usually affect other organs but can cause a greater predisposition to tumors also in the skin. For this reason, knowing the clinical-pathological and genetic aspects of patients affected by these mutations allows for the prevention of skin cancer onset. Further, it also allows for improved prognosis and therapeutic setting, possibly addressing these patients in scheduled follow-ups.
The goal of this Research Topic is to summarize the main genetic mutations in melanocytic and non-melanocytic tumor. Knowledge of the main genetic mutations in cutaneous malignancies allows an increasingly targeted therapy for this class of patients and more efficient follow-ups. Furthermore, the knowledge of genetic mutations in cutaneous tumors and the relative clinic-pathological features, will allow to increase and broaden the therapeutic perspectives, reducing morbidity and mortality, providing important information about the health of the person tested in the absence of definitive treatment, or assisting therapeutic decision-making.
Here, authors are welcomed address the following themes:
•Reviews, original articles and case reports that focus on the main genetic mutations in melanocytic and non-melanocytic tumors are welcome.
•Reviews, original articles and case reports that focus on cutaneous and non-cutaneous genetic mutations that may induce the onset of skin tumors are welcome
•Reviews, original articles and case reports that focus on therapeutic response to topical and systemic treatments of cutaneous tumors which show specific genetic mutations are welcome
• Reviews and original articles that focus on cutaneous diagnostic and baseline clinic-pathologic features in general mutated patients are welcome.
